"Double-Blind Method" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment.
| Descriptor ID |
D004311
|
| MeSH Number(s) |
E05.318.780.300 E05.581.500.300 N05.715.360.780.320 N06.850.520.445.300
|
| Concept/Terms |
Double-Blind Method- Double-Blind Method
- Double Blind Method
- Double-Blind Methods
- Method, Double-Blind
- Methods, Double-Blind
- Double-Masked Method
- Double Masked Method
- Double-Masked Methods
- Method, Double-Masked
- Methods, Double-Masked
- Double-Masked Study
- Double Masked Study
- Double-Masked Studies
- Studies, Double-Masked
- Study, Double-Masked
- Double-Blind Study
- Double Blind Study
- Double-Blind Studies
- Studies, Double-Blind
- Study, Double-Blind
|
Below are MeSH descriptors whose meaning is more general than "Double-Blind Method".
Below are MeSH descriptors whose meaning is more specific than "Double-Blind Method".
This graph shows the total number of publications written about "Double-Blind Method" by people in this website by year, and whether "Double-Blind Method" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 18 | 18 |
| 1996 | 0 | 16 | 16 |
| 1997 | 0 | 31 | 31 |
| 1998 | 0 | 16 | 16 |
| 1999 | 0 | 24 | 24 |
| 2000 | 0 | 22 | 22 |
| 2001 | 0 | 21 | 21 |
| 2002 | 0 | 34 | 34 |
| 2003 | 0 | 33 | 33 |
| 2004 | 0 | 36 | 36 |
| 2005 | 0 | 43 | 43 |
| 2006 | 0 | 37 | 37 |
| 2007 | 0 | 34 | 34 |
| 2008 | 0 | 41 | 41 |
| 2009 | 0 | 55 | 55 |
| 2010 | 0 | 34 | 34 |
| 2011 | 0 | 61 | 61 |
| 2012 | 0 | 51 | 51 |
| 2013 | 0 | 47 | 47 |
| 2014 | 0 | 80 | 80 |
| 2015 | 0 | 56 | 56 |
| 2016 | 0 | 39 | 39 |
| 2017 | 0 | 65 | 65 |
| 2018 | 0 | 61 | 61 |
| 2019 | 0 | 50 | 50 |
| 2020 | 0 | 51 | 51 |
| 2021 | 0 | 50 | 50 |
| 2022 | 0 | 46 | 46 |
| 2023 | 0 | 40 | 40 |
| 2024 | 0 | 48 | 48 |
| 2025 | 0 | 22 | 22 |
To return to the timeline,
click here.
Below are the most recent publications written about "Double-Blind Method" by people in Profiles.
-
Early nintedanib deployment in COVID-19 interstitial lung disease (ENDCOV-I): study protocol of a randomised, double-blind, placebo-controlled trial. BMJ Open Respir Res. 2025 Apr 10; 12(1).
-
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial. Lancet Neurol. 2025 Apr; 24(4):316-330.
-
BIO101 in Sarcopenic Seniors at Risk of Mobility Disability: Results of a Double-Blind Randomised Interventional Phase 2b Trial. J Cachexia Sarcopenia Muscle. 2025 Apr; 16(2):e13750.
-
Mannitol vs placebo for brain relaxation in cerebellopontine angle tumor surgeries: A randomized controlled trial. J Clin Neurosci. 2025 Jun; 136:111199.
-
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Long-term follow-up, crossover, and rechallenge with pembrolizumab in the phase III KEYNOTE-716 study. Eur J Cancer. 2025 May 02; 220:115381.
-
Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76?K trial. Eur J Cancer. 2025 May 02; 220:115371.
-
A phase I study of the safety, reactogenicity and immunogenicity of two quadrivalent seasonal influenza vaccines (Fluzone? or Flublok?) with or without one of two adjuvants (AF03 or Advax-CpG55.2) in healthy adults 18-45?years of age. Vaccine. 2025 Apr 30; 54:126991.
-
Effect of Targeting ApoC-III With Plozasiran on Lipoprotein Particle Size and?Number?in?Hypertriglyceridemia. J Am Coll Cardiol. 2025 May 20; 85(19):1839-1854.
-
Dupilumab reduces acute exacerbations and improves lung function in patients with COPD with type 2 inflammation irrespective of body mass index, airflow obstruction, dyspnea, and exercise capacity index scores. Respir Med. 2025 May; 241:108015.
-
Long-Term Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: An Open-Label Active Treatment (REALISE Study). J Allergy Clin Immunol Pract. 2025 May; 13(5):1190-1200.e3.